Rachel Hall, EY's US Consulting Digital Health and Smart Health Experience Leader, joins us for this episode as we peel back the layers of digital health. Rachel will give her take on the landscape and how each player, patient, physician, and healthcare firm fit into the ecosystem. We also talk about something that's been on everyone's minds lately - and that's artificial intelligence. So join us for this episode of Let's Talk Medtech as we "crack" the digital health code.

Volta Medical is a company that has developed AI software solutions to assist cardiac electrophysiologists in treating atrial fibrillation (AF). Its technology focuses on mapping abnormal regions in the heart during AF procedures and providing cues to optimize the ablation strategy. Unlike other mapping technologies, Volta Medical takes a data-driven approach and aims to replicate the clinical expertise of physicians using machine learning and AI.The company recently completed enrollment for the TAILORED-AF clinical trial, which is a large-scale international trial involving multiple centers and physicians in five countries. The trial enrolled 374 patients who will be followed up for one year. The primary endpoint is freedom from AF after one procedure, with several secondary endpoints related to freedom from arrhythmia.The co-founder of Volta Medical, Theophile Mohr-Durdez, joins this episode of Let's Talk Medtech to talk about the company's technology, long-term goals, and the unique skillset he brings to the table thanks to his experience on stage.

Elucid is changing the way we think about cardiovascular health. To do this, the Boston-based company has appointed medtech veteran, Scott Huennekens as chairman of its board. Scott along with Elucid's CEO Blake Richards joins us for this episode to talk about how the company is changing the way we view cardiovascular health.Plus, Scott discusses his incredible career in this can't-miss episode.

In this episode of Let's Talk Medtech, Babson Diagnostics CEO David Stein discusses the company's progress toward commercialization. Babson has developed a model for diagnostic blood testing that maintains a high standard of accuracy, yet requires only one-tenth the sample size of traditional venipuncture methods. Babson also uses a proprietary blood collection device to collect the sample at a participating pharmacy, then the sample is processed back at Babson's labs.

Hyperfine's President & CEO Maria Sainz tells us how and why Swoop is changing the way we think about MRI's. Plus, she discusses her career in the medtech industry.

Foley & Lardner LLp's, Nathaniel Lacktman joins us for this episode of Let's Talk Medtech to give insight on whether the telemedicine boom the industry saw at the beginning of the pandemic still exists.

maxon's Peter van Beek delves into the latest miniaturization trends in medtech.

Penumbra CEO Adam Elsesser joins Let’s Talk Medtech to discuss the company's newest mechanical thrombectomy devices (Lightning Flash and Lightning Bolt), an ambitious revenue projection, and why failure is an acceptable option at his company.

Galen Robotics's CTO and co-founder Dave Saunders explains why true artificial intelligence in healthcare doesn't exist...yet. 

Don't miss Cordis CEO Shar Matin talking about building a new company from a storied brand, M&A, and what to expect from Cordis now that it is privately owned and solely focused on medtech.